PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

NCT06842199 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT383
EST. COMPLETION2026-05

Conditions

Plaque Psoriasis Patients

Interventions

ICP-488 TabletsICP-488 Placebo

Study details

SPONSORBeijing InnoCare Pharma Tech Co., Ltd.
START DATE2025-03-20

Related company profiles

InnoCare Pharma

9969.HK

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06842199
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record